The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Abstract
Summary: The effect of NRAS mutations on the pathological features and clinical outcomes in patients with cutaneous melanoma was compared with that of tumors containing BRAFV600E mutations and tumors wild type for both (WT). Clinical outcome data were obtained from a prospective cohort of 249 patients. Mutations involving NRAS and BRAFV600E were detected by PCR and were sequence verified. Cox proportional hazards regression was performed to relate NRAS and BRAF mutations to clinical outcome. Seventy‐five percentage of NRAS mutations occurred in tumors >1 mm thick (BRAFV600E 40%, WT 34%); 75% of NRAS mutations had >1 mitosis/mm 2 (BRAFV600E 40%, WT 55%). When compared to WT, multivariate analysis of melanoma‐specific survival (MSS) identified NRAS mutations as an adverse prognostic factor [hazard ratio (HR) 2.96; P = 0.04] but not BRAFV600E mutations (HR 1.73; P = 0.23). NRAS mutations were associated with thicker tumors and higher rates of mitosis when compared to BRAFV600E and WT melanoma and independently of this, with shorter MSS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Jiveskog, S., Ragnarsson-Olding, B., Platz, A., & Ringborg, U. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00376.x · Cited by 155
Cited by
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Resistant mechanisms to BRAF inhibitors in melanoma
Manzano, J. L., Layos, L., Bugés, C., de los Llanos Gil, M., Vila, L., Martínez-Balibrea, E., & Martínez-Cardús, A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.07 · Cited by 255
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Måsbäck, A., Johansson, I., Bendahl, P.-O., Vallon-Christersson, J., Törngren, T., Ekedahl, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0343 · Cited by 105
Metadata
- Authors
- Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C., Dobrovic, A., & McArthur, G.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2011-06-22
- Volume
- 24
- Issue
- 4
- Pages
- 666-672
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W1499291662
- Cited by
- 246
- References
- 4
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. https://app.cochat.ai/papers/10.1111/j.1755-148x.2011.00873.x
- The paper
- Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C., Dobrovic, A., & McArthur, G. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell & Melanoma Research. https://doi.org/10.1111/j.1755-148x.2011.00873.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.